Efficient Cardiomyogenic Differentiation of Embryonic Stem Cell by Fibroblast Growth Factor 2 and Bone Morphogenetic Protein 2

Kawai, Takao; Takahashi, Tomoyuki; Esaki, Masayasu; Ushikoshi, Hiroaki; Nagano, Satoshi; Fujiwara, Hisayoshi; Kosai, Ken‐ichiro

doi:10.1253/circj.68.691

Cited by 120 publications

(85 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…7,13,19,20 Reverse transcription-polymerase chain reaction analysis At 2 days after culturing cells with media in the presence or absence of 50 nM VD 3 (Sigma-Aldrich, Tokyo, Japan), total RNA was extracted from cells and reverse transcription-polymerase chain reaction analyses were performed using the primer sets and annealing temperatures that were described previously. 7,14,21 The osteocalcin/hypoxantine-phosphoribosyl-transferase (a representative housekeeping gene) mRNA ratio was calculated to compare the relative effects of VD 3 in individual cells and standardize the unavoidable variability in the polymerase chain reaction data as described. 21 …”

Section: Cells and Cell Culturementioning

confidence: 99%

See 1 more Smart Citation

Assessment of an altered E1B promoter on the specificity and potency of triple-regulated conditionally replicating adenoviruses: implications for the generation of ideal m-CRAs

et al. 2011

View full text Add to dashboard Cite

Although previous studies modified two components of conditionally replicating adenoviruses (CRAs), which selectively replicate in and kill cancer cells, the most accurate ways to achieve increased cancer specificity (that is, safety) without reducing the anticancer (that is, therapeutic) effects are unknown. Here, we generated two types of survivin-responsive m-CRAs (Surv.mCRAs), Surv.m-CRA-CMVp and Surv.m-CRA-OCp, which use two and three different mechanisms to target cancer, that is, early region 1A (E1A) regulated by the survivin promoter and mutated E1BD55K regulated by the ubiquitously active cytomegalovirus promoter and cancer/tissue-specific osteocalcin promoter, respectively, and carefully examined their safety and anticancer effects. Endogenous osteocalcin mRNA was expressed and further enhanced by vitamin D 3 in all osteosarcoma and prostate cancer cell lines and human osteoblasts, but not in human fibroblasts. The osteocalcin promoter activity was weak even with vitamin D 3 treatment in these osteocalcin-expressing cancers, leading to low E1BD55K expression after Surv.m-CRA-OCp infection. Nevertheless, Surv.m-CRA-OCp had significantly increased cancer specificity without reduced anticancer effects in both in vitro and in vivo experiments. The unexpected but favorable fact that strong activity of an altered E1B promoter is unnecessary indicates that the majority of cancer/tissue-specific promoters may be used to generate ideal m-CRAs and will advance the development of m-CRA-based cancer therapies.

show abstract

Section: Cells and Cell Culturementioning

confidence: 99%

“…7,14,21 The osteocalcin/hypoxantine-phosphoribosyl-transferase (a representative housekeeping gene) mRNA ratio was calculated to compare the relative effects of VD 3 in individual cells and standardize the unavoidable variability in the polymerase chain reaction data as described. 21 …”

Section: Cells and Cell Culturementioning

confidence: 99%

Assessment of an altered E1B promoter on the specificity and potency of triple-regulated conditionally replicating adenoviruses: implications for the generation of ideal m-CRAs

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Unlike adult stem cells, ESC retain the ability to differentiate into specialized cells from all three germ layers. Moreover, it is possible to guide ESC differentiation thru the mesodermal lineage to generate cardiomyocytes [46,47]. This can be accomplished by utilizing the hanging-drop method which creates pseudo-embryos (Fig.…”

Section: Embryonic Stem Cells (Esc)mentioning

confidence: 99%

Adhesion Proteins, Stem Cells, and Arrhythmogenesis

Gillum

Sarvazyan

2008

Cardiovasc Toxicol

View full text Add to dashboard Cite

Cell-transplantation therapy is a promising treatment option that is being actively explored as a way to repair cardiac muscle. The ultimate goal is to reconstitute the architecture of the cardiac muscle and to reestablish electrical propagation, while avoiding hypertrophy and scar formation. In this review, we focus on recent advances in the field as well as the difficulties encountered when the engraftment of cells into the host tissue is to be confirmed and functionally characterized. This is critical since incomplete or partial engraftment of transplanted cells within the host cardiac network exacerbates the heterogeneity already present in the injured myocardium and increases its propensity to arrhythmia. We conclude with a brief discussion of how the modulation of cell adhesion via modification of coupling proteins within transplanted cells may facilitate engraftment and alleviate the arrhythmogenic potential of cardiac grafts.

show abstract

“…For example, a number of studies have implicated signaling of BMP and Wnt family members in cardiomyogenic differentiation of ES cells (Winnier et al 1995;Czyz and Wobus 2001;Behfar et al 2002;Kawai et al 2004;Terami et al 2004). In addition, signaling through the FGF (Dell'Era et al 2003;Kawai et al 2004), IGF-II (Morali et al 2000), Crypto (Parisi et al 2003), PDGFBB (Sachinidis et al 2003), CT-1 (Sauer et al 2004), TGF-beta (Behfar et al 2002), and dynorphin B (Ventura et al 2003) pathways enhanced cardiomyogenesis during EB differentiation. Perhaps not unexpectedly, cytokine/growth factor treatments were occasionally observed to promote cardiomyogenic differentiation via rather indirect mechanisms.…”

Section: Identification Of Factors That Enhance Cardiomyogenic Differmentioning

confidence: 99%

Cardiac Repair by Embryonic Stem-Derived Cells

Rubart

Field

2006

Stem Cells

View full text Add to dashboard Cite

Cell transplantation approaches offer the potential to promote regenerative growth of diseased hearts. It is well established that donor cardiomyocytes stably engraft into recipient hearts when injected directly into the myocardial wall. Moreover, the transplanted donor cardiomyocytes participate in a functional syncytium with the host myocardium. Thus, transplantation of donor cardiomyocytes resulted in at least partial restoration of lost muscle mass. It is also well established that embryonic stem (ES) cells differentiate into cells of ecto-, endo-, and mesodermal lineages when cultured under appropriate conditions in vitro. Robust cardiomyogenic differentiation was frequently observed in spontaneously differentiating ES cultures. Cellular, molecular and physiologic analyses indicated that ES-derived cells were bona fide cardiomyocytes, with in vitro characteristics typical for cells obtained from early stages of cardiac development. Thus, ES-derived cardiomyocytes constitute a viable source of donor cells for cell transplantation therapies.

show abstract

Efficient Cardiomyogenic Differentiation of Embryonic Stem Cell by Fibroblast Growth Factor 2 and Bone Morphogenetic Protein 2

Cited by 120 publications

References 42 publications

Assessment of an altered E1B promoter on the specificity and potency of triple-regulated conditionally replicating adenoviruses: implications for the generation of ideal m-CRAs

Assessment of an altered E1B promoter on the specificity and potency of triple-regulated conditionally replicating adenoviruses: implications for the generation of ideal m-CRAs

Adhesion Proteins, Stem Cells, and Arrhythmogenesis

Cardiac Repair by Embryonic Stem-Derived Cells

Contact Info

Product

Resources

About